European journal of nuclear medicine and molecular imaging
A true theranostic pair - 44/47Sc-labeled GRPR antagonist shows great promise for managing prostate and breast cancer.
Naveen Kumar, Adrianna Bilinska, Elena Menéndez, Tilman Läppchen, Euy Sung Moon, Malgorzata Zoltowska, Dariusz Pawlak, Izabela Cieszykowska, Renata Mikolajczak, Frank Rösch, Axel Rominger, Eleni Gourni
Published: 202510.1007/s00259-025-07651-y
Abstract
PURPOSE: This study investigates the theranostic potential of a 44/47Sc-labeled antagonist targeting the gastrin-releasing peptide receptor (GRPR) in prostate and breast tumors. METHODS: A statine-based GRPR antagonist (AAZTA5-Pip-D-Phe-Gln-Trp-Ala-V…
Preview only. Read the full abstract at the source